Answers are grounded in this paper and cite their sources.
Introduction: Gestational diabetes mellitus (GDM) is associated with adverse maternal and neonatal outcomes. Conventional biomarkers such as random blood sugar (RBS) and glycated hemoglobin (HbA1c) have limitations during pregnancy, whereas fructosamine-based markers may provide information on recent glycemic exposure. Aim: To compare conventional and fructosamine-based glycemic biomarkers between women with GDM and those without GDM during late pregnancy and assess maternal and neonatal outcomes. Methodology: This hospital-based prospective cohort study was conducted at HIMSR and HAHC Hospital, New Delhi, among 200 third-trimester singleton pregnant women (100 (50%) with GDM diagnosed by a 75-g oral glucose tolerance test (OGTT) ≥ 140 mg/dL at 24-28 weeks according to 2018 national guidelines and 100 (50%) non-GDM controls) recruited consecutively from the antenatal clinic with written consent. Women with multiple pregnancies, thyroid, autoimmune, or systemic diseases, and those using steroids were excluded. Research procedures included venous blood collection at 30-32 and 34-36 weeks for RBS (hexokinase method), HbA1c (high-performance liquid chromatography (HPLC)), fructosamine (nitroblue tetrazolium (NBT)), and albumin (bromocresol green (BCG)) measurements to calculate albumin-corrected fructosamine (ACF) (ACF = (fructosamine/albumin) × 30) and fructosamine-to-albumin ratio (FAR) (FAR = fructosamine/albumin). Participants were prospectively followed until delivery to assess maternal (mode of delivery and induction) and fetal (Apgar score and birth weight) outcomes. The sample size was calculated based on a GDM prevalence of 19.2%, yielding 93 participants, which was rounded to 100 per group. Data were analyzed using SPSS version 26 (IBM Corp., Armonk, NY), with mean ± SD, independent and paired t-tests, and the chi-square test. Statistical significance was set at P < 0.05. Results: At 30-32 weeks of gestation, all biomarkers were significantly higher in women with GDM: RBS (102.16 ± 19.79 vs. 95.59 ± 14.92 mg/dL; P = 0.009), HbA1c (5.06 ± 0.51% vs. 4.77 ± 0.40%; P < 0.001), fructosamine (234.61 ± 31.15 vs. 215.67 ± 21.31 µmol/L; P < 0.001), ACF (205.02 ± 59.24 vs. 170.43 ± 35.49 µmol/L; P < 0.001), and FAR (6.83 ± 1.97 vs. 5.68 ± 1.18 µmol/g; P < 0.001). At 34-36 weeks, HbA1c, fructosamine, ACF, and FAR remained significantly higher in women with GDM, whereas RBS did not differ significantly between the groups. GDM was also associated with higher rates of labor induction and cesarean delivery and a lower 1-minute Apgar score. However, birth weight was comparable between the groups (2,997.39 ± 387.63 g vs. 2,994.19 ± 392.00 g; P = 0.954). Conclusions: Fructosamine, ACF, and FAR may provide useful complementary information for monitoring glycemic status in women with established GDM during late pregnancy.
No takes yet. Share an insight, caveat, or question.
Devi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: